Oral idarubicin pharmacokinetics - Correlation of trough level with idarubicin area under curve

Leukemia

Volumn 10, Issue 4, 1996, Pages 707-712

  Schleyer, E ^a   Kuhn S ^a   Ruhrs H ^a   Unterhalt, M ^a   Kaufmann, C C ^a   Kern, W ^a   Braess, J ^a   Straubel G ^a   Hiddemann, W ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Idarubicin; Minimal sampling strategy; Pharmacokinetics

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DRUG METABOLITE; IDARUBICIN; IDARUBICINOL;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DRUG HALF LIFE; HUMAN; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029978001     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Robert J, Rigal-Huguet F, Harousseau JL, Pris J, Huet S, Reiffers J, Hurtelopu P, Tamassia V. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Leukemia Res 1987; 11: 961-964.
2. Elbaek K, Ebbehoej E, Jakobsen A, Juul P, Rasmusen S, Bastholt L, Dalmark M, Steiness E. Pharmacokinetics of oral idarubicin in breast cancer with reference to antitumor activity and side-effects. Clin Pharmacol Ther 1989; 5: 627-634.
3. Di Marco A, Casazza AM, Pratesi G. Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 1977; 61: 893-894.
4. Harousseau JL, Pignon B, Reiffers J, Rigal-Huguet F, Cahn JY, Le PY. Toxicity profile of idarubicin with oral and intravenous idarubicin in the treatment of leukemia. In: Hiddemann W et al. Haematology and Blood Transfusion, Vol 34: Acute Leukemias-Pharmacokinetics. Springer Verlag: Berlin, 1992, pp 625-631.
5. Tamassia V, Pacciarini MA, Moro E, Piazza E, Vago G, Libretti A. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients. Int J Clin Pharmacol Res 1987; 5: 419-426.
6. Speth PAJ, van de Loo FAJ, Linssen PCM et al. Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunorubicm. Clin Pharmacol Ther 1986; 40: 643-649.
7. Pannuti F, Camaggi CM, Strocchi E, Comparsi R, Angelelli B, Paciarini MA Low-dose oral administration of 4-demethoxydaunorubicin (idarubicin) in advanced cancer patients. Cancer Chemother Pharmacol 1986; 16: 295-299.
8. Smith DB, Margison JM, Lucas SB, Wilkinson PM, Howell A. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemother Pharmacol 1987; 19: 138-142.
9. Gillies HC, Herriott D, Liang R, Ohashi K, Rogers HI, Harper PG. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer. Br J Clin Pharmacol 1987; 23: 303-310.
10. Lu K, Savaraj N, Kavanagh J, Lynn GF, Burgess M, Bodey GP, Loo TL. Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 1968; 17: 143-148.
11. Berman E, Wittes RE, Leyland-Jones B, Casper ES, Gralla RJ, Howard J, Williams L, Baratz R, Young CW. Phase I and clinical pharmacology studies of intravenous and oral administration of 4- demethoxydaunorubicin in patients with advanced cancer. Cancer Res 1983; 43: 6096-6101.
12. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, Clarkson BD, Young CW. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia. Cancer Res 1985; 45: 1408-1412.
13. Camaggi CM, Strocchi E, Carisi P, Martoni A, Tononi A, Guaraldi M, Strolin-Benedetti M, Efthymiopoulos C, Pannuti F. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol 1992; 30: 307-316.
14. Reid JM, Kuffel MJ, Pendergrass TW et al. Cytotoxic concentrations of idarubicinol, the alcohol metabolite of idarubicin are present in CSF following administration of idarubicm to children with relapsed leukemia. Proc Am Assoc Cancer Res 1989; 30 250.
15. Ames MM, Spreafico F. Selected pharmacologic characteristics o: idarubicin and idarubicinol. Leukemia 1992; 6: (Suppl 1) 70-75
16. Heinzel G, Hammer R, Wolf M, Koss FW, Bozler G. Modellentwicklung in der Pharmakokinetik. Drug Res 1977; 27: 904-911.
17. Schleyer E, Budeus S, Reinhardt J, Rolff C, Buchner T, Hiddemanr W. Idarubicin pharmacokinetics. In: Hiddemann W et al. Haema tology and Blood Transfusion, Vol 34: Acute Leukemias - Pharmacokinetics. Springer Verlag: Berlin, 1992, pp 617-624.